 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
(Continued
from page 16)
|
By William Palumbo,
MS, RD, CDN |
|
|
|
|
Pharmacodynamics/Kinetics:
Bioavailability:
increases with chronic dosing
Half-Life Elimination:
40 hours
Excretion: Urine
Absorption: In
a single-dose pharmacokinetic study, Ribavirin taken with a high-fat meal
(841 calories, 53.8 grams (g) fat, 31.6 g protein, and 57.4 g carbohydrate)
increased drug absorption. Coadministration of Ribavirin with an antacid
containing magnesium, aluminum, and simethicone resulted in a decrease
in drug absorption. The primary toxicity of Ribavirin is hemolytic anemia.
Dosage Forms: Powder
for injection: 50mcg/0.5mL, 80mcg/0.5mL, 120mcg/0.5mL, 150mcg/0.5mL.
|
|
|
|
Usual
Dosage: <45kg: 40mcg; 46-56kg: 50mcg; 57-72kg: 64mcg; 73-88kg: 80mcg;
89-106kg: 96mcg; 107-136kg: 120mcg; 137-160kg: 150mcg.
Administration:
For subcutaneous administration; rotate injection site. |
|
|
|
|
|
|
|
|
"In a single-dose pharmacokinetic
study, Ribavirin taken with a high-fat meal (841 calories, 53.8 grams (g)
fat, 31.6 g protein, and 57.4 g carbohydrate) increased drug absorption."
|
|
|
|
|
|
|
|
Monitoring
Parameters: Baseline and periodic thyroid stimulating hormone, hematology
(including CBC with differential, platelets), and chemistry (including
liver function labs) testing.
Precautions: Users
should drink lots of fluids during initial treatment to reduce nausea and
dehydration. Diabetes, hyperglycemia, and decreased platelets have been
observed. Safety and effectiveness in HIV-positive people, in pregnant
women and pediatric patients is not adequately established.
For additional information
on this drug visit the Product Approval Information at the Food
and Drug Administration web site. View information on Pegetron, the
combination of peginterferon and Ribavirin sold in Canada at the CATIE
web site.
References
-
Lacy C, et al. Drug Information
Handbook. 2002-2003. 10th Edition. Lexi-Comp, Inc: Hudson, OH; 2002:
1047-1048.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No
part of this newsletter may be reproduced in any form without permission
from the publisher. Copyright 2003 HIV ReSources, Inc. Email: subscriptions@hivresources.com |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
